// App-Quantinova.ai

1716 : Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Researchers

Presenter

  • Jo Howard

Principal Investigators

  • Kenneth I. Ataga

  • R. Clark Brown

  • Maureen Achebe

  • Videlis Nduba

  • Amal El-Beshlawy

  • Hoda Hassab

  • Irene Agodoa

  • Margaret Tonda

  • Sarah Gray

  • Joshua Lehrer-Graiwer

  • Elliott Vichinsky

Medical Centers

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • The University of Tennessee Health Science Center, Memphis, TN

  • Aflac Cancer & Blood Disorders Center of Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA

  • Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

  • Kenya Medical Research Institute, Kisumu, Kenya

  • Cairo University, Cairo, Egypt

  • Pediatric Department and Clinical Research Center, Faculty of Medicine, Alexandria University, Alexandria, Egypt

  • Global Blood Therapeutics, South San Francisco, CA

  • UCSF Benioff Childrens Hospital Oakland, Oakland, CA

Locations

  • United Kingdom

  • United States

  • Kenya

  • Egypt

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Sickle cell anemia

Biomarkers

  • Stearoyl-CoA desaturase

Drug/Treatment

  • Hydroxyurea

  • Hydroxycarbamide

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved